الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 123 |  |  |
| | | from | 123 | | |
Abstract
• Introduction: Lupus nephritis (LN) represents one of the most important and most dangerous complications of systemic lupus erythematosus affecting more than half of the SLE patients, Renal biopsy is the “gold standard” for diagnosis of LN. It is necessary for classification and is the basis for treatment strategy decisions. Aim of the work: This study was carried out in order to analyse the results of renal biopsy in LN patients, its effect on treatment and predictors for remission. Patient and methods: A total of 100 biopsy proven LN patients were enrolled in this study and completed followed up for a minimum of 6 months for every patient. The results of renal biopsies of LN patients undergoing regular follow up in the outpatient clinic of Mansoura Nephrology and Dialysis Unit (MNDU) during the period between March 2018 and September 2019 were reviewed. The histopathological data were analyzed and correlated to the clinical data of the study group. Results: Class IV (diffuse proliferative) LN was the most frequently encountered class (54%), followed by Classes III, V, II and VI respectively, while class I was detected in only one patient. Steroids in addition mycophenolate mofetil (MMF) and cyclophosphamide were the most frequently used. Remission was achieved in 73 patients Patients who achieved remission had lower serum creatinine and lower pathological chronicity score. Serum creatinine at presentation was the strongest predictor for renal remission in this cohort (n=100) with a level lower than 1.65 mg/dl can indicate the probability of renal recovery. On the other hand among proliferative classes (III and IV) (n=73) chronicity index was the strongest predictor with a value of 6 or less identifies the probability of renal recovery. Conclusion: Renal biopsy is a must in LN to guide treatment and prognosis. Serum creatinine at presentation and pathological chronicity index score are strong predictors of response in LN patients.